share_log

Invivyd | 8-K: Current report

Invivyd | 8-K: Current report

Invivyd | 8-K：重大事件
SEC announcement ·  04/12 19:41
牛牛AI助手已提取核心信息
Invivyd, Inc., a biopharmaceutical company, has announced a significant change in its executive leadership. David Hering, the CEO of Invivyd, has stepped down from his role and as a member of the company's Board of Directors, effective April 11, 2024. His employment with the company will officially end on May 11, 2024. The Board is actively searching for a permanent replacement. Concurrently, Jeremy Gowler, who has been with Invivyd as Chief Operating Officer and Chief Commercial Officer since December 2022, has been appointed as the Interim CEO. Gowler's extensive experience includes roles at Sandoz, a division of Novartis, and Emergent Biosolutions. He will continue to fulfill his previous roles while serving as Interim CEO and will collaborate with an executive committee for strategic...Show More
Invivyd, Inc., a biopharmaceutical company, has announced a significant change in its executive leadership. David Hering, the CEO of Invivyd, has stepped down from his role and as a member of the company's Board of Directors, effective April 11, 2024. His employment with the company will officially end on May 11, 2024. The Board is actively searching for a permanent replacement. Concurrently, Jeremy Gowler, who has been with Invivyd as Chief Operating Officer and Chief Commercial Officer since December 2022, has been appointed as the Interim CEO. Gowler's extensive experience includes roles at Sandoz, a division of Novartis, and Emergent Biosolutions. He will continue to fulfill his previous roles while serving as Interim CEO and will collaborate with an executive committee for strategic guidance. In addition, the Board has reduced its size from nine to eight members. The company has also issued a press release on April 12, 2024, detailing these management changes and highlighting the company's focus on delivering monoclonal antibody therapies for the prevention of COVID-19. Invivyd's lead product, PEMGARDA™, has shown promise in clinical trials and has been authorized for emergency use by the U.S. FDA for certain immunocompromised individuals.
生物制药公司Invivyd, Inc. 宣布其执行领导层发生重大变动。Invivyd首席执行官大卫·赫林已辞去公司董事会成员的职务，自2024年4月11日起生效。他在公司的工作将于2024年5月11日正式结束。董事会正在积极寻找永久替代者。同时，自2022年12月起在Invivyd担任首席运营官兼首席商务官的杰里米·高勒被任命为临时首席执行官。高勒的丰富经验包括在诺华旗下的山德士和Emergent Biosolutions担任过职务。在担任临时首席执行官期间，他将继续履行先前的职务，并将与执行委员会合作提供战略指导。此外，该委员会已将其成员人数从九名减少到八名。该公司还于2024年4月12日发布了一份新闻稿，详细介绍了这些管理层变动，并强调了该公司专注于提供预防 COVID-19 的单克隆抗体疗法。Invivyd的主要产品PEMGARDA™ 已在临床试验中显示出希望，并已获得美国食品药品管理局的批准，可供某些免疫功能低下的人紧急使用。
生物制药公司Invivyd, Inc. 宣布其执行领导层发生重大变动。Invivyd首席执行官大卫·赫林已辞去公司董事会成员的职务，自2024年4月11日起生效。他在公司的工作将于2024年5月11日正式结束。董事会正在积极寻找永久替代者。同时，自2022年12月起在Invivyd担任首席运营官兼首席商务官的杰里米·高勒被任命为临时首席执行官。高勒的丰富经验包括在诺华旗下的山德士和Emergent Biosolutions担任过职务。在担任临时首席执行官期间，他将继续履行先前的职务，并将与执行委员会合作提供战略指导。此外，该委员会已将其成员人数从九名减少到八名。该公司还于2024年4月12日发布了一份新闻稿，详细介绍了这些管理层变动，并强调了该公司专注于提供预防 COVID-19 的单克隆抗体疗法。Invivyd的主要产品PEMGARDA™ 已在临床试验中显示出希望，并已获得美国食品药品管理局的批准，可供某些免疫功能低下的人紧急使用。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。